Reply
- PMID: 35503722
- DOI: 10.1002/hep.32553
Reply
References
-
- D’Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, Felden J, Schulze K, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study. Hepatology. 2022;76:1000–12.
-
- Fang P, Hu JH, Cheng ZG, Liu ZF, Wang JL, Jiao SC. Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials. PLoS One. 2012;7(12):e49717.
-
- Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–73.
-
- Pinato DJ, Scotti L, Gennari A, Colomba‐Blameble E, Dolly S, Loizidou A, et al. Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. Eur J Cancer. 2021;150:190–202.
-
- Pinato DJ, Zambelli A, Aguilar‐Company J, Bower M, Sng CCT, Salazar R, et al. Clinical portrait of the SARS‐CoV‐2 epidemic in European patients with cancer. Cancer Discov. 2020;10(10):1465–74.
Publication types
LinkOut - more resources
Full Text Sources
